Loading data for CLRB — first visit, this takes a few seconds.
Cellectar Biosciences Inc... (CLRB)
NasdaqCM: CLRB
· Real-Time Price · USD
2.54
-0.04 (-1.55%)
At close: Aug 27, 2026, 3:59 PM
The price, the headline numbers and the latest news, in one place.
Cellectar Biosciences Inc. (CLRB) Stock Price, Analysis & Data
-1.55% (1D)
| Bid | 1.8 |
| Market Cap | 23.72M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -22.32M |
| 0.56 | |
| -2.21 | |
| n/a | |
| -1.31 | |
| P/B (ttm) | 0.69 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 12, 2026 |
| Ask | 3.32 |
| Volume | 10,103 |
| Avg. Volume (20D) | 94,382 |
| Open | 2.57 |
| Previous Close | 2.58 |
| Day's Range | 2.52 - 2.57 |
| 52-Week Range | 2.20 - 6.52 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CLRB
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobu...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 10, 2005
Employees 11
Stock Exchange NasdaqCM
Ticker Symbol CLRB
Website https://www.cellectar.com
Financial Performance
In 2025, Cellectar Biosciences's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -21.79M, a decrease of -51.12%.
Financial StatementsEarnings Surprise
Cellectar Biosciences has released their quarterly earnings on Aug 13, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.57 misses estimates by -0.05, with 83.19% YoY growth.
Cellectar Biosciences Inc. is scheduled to release its earnings on Nov 12, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2